# US 2002/0055667 A1 · Absorbable brachytherapy and chemotherapy delivery devices and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0055667 A1
- Document ID: US20020055667A1
- Status: Published application
- Kind: A1
- Application number: 09/845,035
- Filed: 2001-04-27
- Published: 2002-05-09
- Earliest claimed: 1998-07-28
- Inventors: William Mavity; Robert Stern; Shigemasa Osaki; Paul Zamora
- Web page: https://patentgrep.com/patent/US20020055667A1

## CPC

- A61N 5/1027: {Interstitial radiation therapy}
- A61N 2005/1019: {Sources therefor}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

Combination radiation delivery and chemotherapy devices comprise bioabsorbable structures with radionuclides and chemotherapeutic agents immobilized on said structures. The bioabsorbable structures have a predefined persistence period which is usually substantially greater than the half-life of the radionuclides, thus assuring that the radionuclides remain localized and sequestered at a desired target site while significant radioactivity remains. The radiation delivery and chemotherapy devices are suitable for a wide variety of medical purposes, being particularly suitable for the treatment of solid tumors by injection or open surgical introduction of the devices at a target site. Kits comprising the devices together with instructions for use are also provided.

## Claims

### Claim 1

A radiation delivery device, said device comprising:
a bioabsorbable structure having a predefined persistence period when implanted in a patient; and
a radionuclide having a known half-life immobilized on said structure, where the persistence period of the bioabsorbable structure is substantially longer than a half-life of the radionuclide so that loss of radioactivity from the target site is minimized.

### Claim 2 (depends on 1)

A radiation delivery device as in claim 1, wherein the bioabsorbable structure has a persistence period in the range from 2 days to 90 days.

### Claim 3 (depends on 1, 2)

A radiation delivery device as in claim 1 or 2, wherein the radionuclide has a half-life of 60 days or less.

### Claim 4 (depends on 1, 2)

A radiation device as in claims 1 or 2, wherein the biodegradable structure is composed of a biological polymer.

### Claim 5 (depends on 1, 4)

A radiation device as in claims 1 or 4, wherein the biodegradable structure has a drug incorporated into said structure.

### Claim 6 (depends on 5)

A radiation device as in claim 5, wherein the drug incorporated into the biodegradable structure is substantially released within two half-lives of the radionuclide.

### Claim 7 (depends on 5)

A radiation device as in claim 5, wherein the drug incorporated into the biodegradable structure is a chemotherapeutic agent.

### Claim 8 (depends on 1, 4)

A radiation delivery device as in claim 1 or 4, wherein the biodegradable structure is formed as an implantable macrostructure comprising a continuous core structure with a minimum width of at least 1 mm.

### Claim 9 (depends on 1, 4)

A radiation delivery device as in claim 1 or 4, wherein the biodegradable structure is formed as an implantable microstructure comprising core particles having an average width below 1 mm.

### Claim 10 (depends on 1)

A radiation delivery device as in claim 1, wherein the radionuclide is selected from the group consisting of Cu-162, Cu-64, Cu-67, Ru-97, Rh-105, Pd-109, Sm-153, Ho-166, Re-186, Re-188, Au-198, Au-199, Pb-203, Pb-211, Bi-212, 1-125, I-131, Y-90, Pd-103, Ir-192 and P-32.

### Claim 11 (depends on 1)

A radiation delivery device as in claim 1, wherein the radionuclide is covalently bound to a preformed surface on the bioabsorbable structure.

### Claim 12 (depends on 11)

A radiation delivery device as in claim 11, wherein the radionuclide is covalently bound through a linker which is bound to the surface.

### Claim 13 (depends on 1)

A radiation delivery device as in claim 1, wherein the radionuclide is chelated, adsorbed, precipitated, or complexed to a preformed surface on the bioabsorbable surface.

### Claim 14 (depends on 1)

A radiation delivery device as in claim 1, wherein the radionuclide is suspended within a substance or mixed with a substance which undergoes gelation, solation, or solidification upon introduction into the body.

### Claim 15 (depends on 1)

A method for localized delivery of radioactivity to a target site in tissue, said method comprising implanting a radiation delivery device according to claim 1 at said target site.

### Claim 16 (depends on 5)

A method for localized delivery of radioactivity and drugs to a target site in tissue, said method comprising implanting a radiation delivery device according to claim 5 at said target site.

### Claim 17 (depends on 15, 16)

A method as in claims 15 or 16, wherein the radiation delivery device comprises an injectable matrix and implanting comprising injecting the matrix to said site.

### Claim 18 (depends on 15, 16)

A method as in claim 15 or 16, wherein implanting comprises surgically exposing the target site and placing the device at the surgically exposed site.

### Claim 19

A method for preparing a treatment delivery device, said method comprising:
providing a bioabsorbable structure having a predefined persistence period and a surface wherein at least a portion of the surface has been coated with a substrate material;
providing a radioactive material including a bonding constituent which can be bonded to the substrate material and a radioactive isotope, where the persistence period of the bioabsorbable structure is substantially longer than a half-life of the radionuclide;
determining the specific activity of the radioactive material; and
bonding an amount of the radioactive material to the substrate material on the device selected to provide a predetermined radioactive dosage.

### Claim 20 (depends on 19)

A method as in claim 19, wherein the predetermined dosage is in the range from 20 gray to 200 gray.

### Claim 21 (depends on 19)

A method as in claim 19, wherein the bioabsorbable structure has a persistence period in the range from 2 days to 90 days.

### Claim 22 (depends on 19, 21)

A method as in claim 19 or 21, wherein the radionuclide has a half-life of 60 days or less.

### Claim 23 (depends on 19)

A method as in claim 19, wherein the bonding step comprises covalently bonding the radioactive material to the substrate material.

### Claim 24 (depends on 19)

A method as in claim 19, wherein the biodegradable structure is composed of a biological polymer.

### Claim 25 (depends on 19, 24)

A method as in claim 19 or 24, wherein the biodegradable structure is formed as an implantable macrostructure comprising a continuous core structure with a minimum width of at least 1 mm.

### Claim 26 (depends on 19, 24)

A method as in claim 19 or 24, wherein the biodegradable structure is formed as an implantable microstructure comprising core particles having an average width below 1 mm.

### Claim 27 (depends on 19)

A method as in claim 19, wherein the substrate material is selected from the group consisting of siloxanes and bifunctional chelating agents.

### Claim 28 (depends on 19)

A method as in claim 19, wherein the radioactive material comprises a radionuclide and a bonding component.

### Claim 29 (depends on 19)

A method as in claim 19, wherein the bioabsorbable structure has dispersed therein a drug.

### Claim 30 (depends on 19)

A method as in claim 19, further comprising the steps of:
providing a sustained release drug material which can be bonded to the substrate material, where the persistence period of the bioabsorbable structure is substantially longer than the period required to release substantially release the drug; and
bonding an effective amount of the sustained release drug material to the substrate material on the device.

### Claim 31 (depends on 29, 30)

A method as in claims 29 or 30, wherein the drug is a chemotherapeutic drug.

### Claim 32 (depends on 1)

A kit comprising:
a radiation delivery device according to claim 1; and
instructions describing a method for implanting the device in tissue.

### Claim 33 (depends on 32)

A kit as in claim 32, further comprising a package which contains the device and the instructions.

### Claim 34 (depends on 33)

A kit as in claim 33, wherein the instructions further set forth a method for coating the radiation delivery device with a radioactive material prior to implantation.
